JOHNSON HEALTH TECH .CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.4 TWD | -0.23% |
|
-7.10% | +25.76% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 25,756 | 28,020 | 17,036 | 21,030 | 20,811 | 26,233 | - |
| Enterprise Value (EV) 1 | 32,447 | 34,845 | 30,440 | 34,097 | 20,811 | 26,233 | 26,233 |
| P/E ratio | 20 x | 41.3 x | 433 x | 48.9 x | 29.4 x | 23.3 x | 17.4 x |
| Yield | 1.65% | 1.21% | - | - | - | 2.89% | 3.46% |
| Capitalization / Revenue | 1.02 x | 0.99 x | 0.55 x | 0.63 x | 0.55 x | 0.65 x | 0.61 x |
| EV / Revenue | 1.02 x | 0.99 x | 0.55 x | 0.63 x | 0.55 x | 0.65 x | 0.61 x |
| EV / EBITDA | 10.4 x | 14.6 x | - | 21.2 x | 7.88 x | 6.68 x | 6.55 x |
| EV / FCF | 87.1 x | 12.9 x | -4.06 x | -1,373 x | - | 24.1 x | 11.1 x |
| FCF Yield | 1.15% | 7.75% | -24.6% | -0.07% | - | 4.16% | 9.01% |
| Price to Book | 2.82 x | 3.01 x | 2.01 x | 2.22 x | - | - | - |
| Nbr of stocks (in thousands) | 303,017 | 302,589 | 302,589 | 302,589 | 302,922 | 302,922 | - |
| Reference price 2 | 85.00 | 92.60 | 56.30 | 69.50 | 68.70 | 86.60 | 86.60 |
| Announcement Date | 3/19/20 | 3/25/21 | 3/23/22 | 3/15/23 | 3/15/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 25,373 | 28,367 | 30,779 | 33,613 | 38,070 | 40,398 | 42,690 |
| EBITDA 1 | 2,486 | 1,914 | - | 991.6 | 2,640 | 3,927 | 4,002 |
| EBIT 1 | 1,609 | 930.1 | 154.2 | -214.9 | 1,242 | 1,669 | 2,180 |
| Operating Margin | 6.34% | 3.28% | 0.5% | -0.64% | 3.26% | 4.13% | 5.11% |
| Earnings before Tax (EBT) 1 | 1,617 | 975.3 | 163.7 | 303.6 | 1,334 | 1,608 | 2,014 |
| Net income 1 | 1,293 | 679.3 | 38.15 | 429 | 709.8 | 1,127 | 1,514 |
| Net margin | 5.09% | 2.39% | 0.12% | 1.28% | 1.86% | 2.79% | 3.55% |
| EPS 2 | 4.260 | 2.240 | 0.1300 | 1.420 | 2.340 | 3.710 | 4.985 |
| Free Cash Flow 1 | 295.7 | 2,170 | -4,194 | -15.32 | - | 1,090 | 2,364 |
| FCF margin | 1.17% | 7.65% | -13.63% | -0.05% | - | 2.7% | 5.54% |
| FCF Conversion (EBITDA) | 11.9% | 113.39% | - | - | - | 27.76% | 59.06% |
| FCF Conversion (Net income) | 22.88% | 319.5% | - | - | - | 96.72% | 156.19% |
| Dividend per Share 2 | 1.400 | 1.120 | - | - | - | 2.500 | 3.000 |
| Announcement Date | 3/19/20 | 3/25/21 | 3/23/22 | 3/15/23 | 3/15/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,741 | 7,527 | 6,567 | 8,029 | 11,490 | 7,035 | 8,636 | 9,676 | 12,722 | 8,026 | 9,329 | 10,020 | 13,023 | 8,080 | 9,639 |
| EBITDA 1 | - | - | - | 223 | 1,126 | -278 | 431.3 | 845.8 | - | - | 735 | 1,120 | 1,892 | - | - |
| EBIT 1 | 632.1 | -175.1 | -750.7 | -115.5 | 826.3 | -589.9 | 89.02 | 460.9 | 1,263 | -331.8 | 196 | 581 | 1,224 | -326 | 88 |
| Operating Margin | 6.49% | -2.33% | -11.43% | -1.44% | 7.19% | -8.38% | 1.03% | 4.76% | 9.93% | -4.13% | 2.1% | 5.8% | 9.4% | -4.03% | 0.91% |
| Earnings before Tax (EBT) 1 | 568 | 101.2 | -538.1 | 10.29 | 730.2 | -716.5 | 483.7 | 561.4 | 1,006 | -50.06 | 165 | 532 | 859 | -335 | 125 |
| Net income 1 | 474.5 | 82.03 | -410.3 | 223.2 | 534.1 | -646.8 | 333.3 | 369.5 | 653.7 | -137.9 | 122 | 388 | 653 | -261 | 96 |
| Net margin | 4.87% | 1.09% | -6.25% | 2.78% | 4.65% | -9.19% | 3.86% | 3.82% | 5.14% | -1.72% | 1.31% | 3.87% | 5.01% | -3.23% | 1% |
| EPS 2 | - | 0.2700 | -1.360 | 0.7400 | 1.770 | -2.140 | 1.100 | 1.220 | 2.150 | -0.4600 | 0.4000 | 1.280 | 2.160 | -0.8600 | 0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/22 | 5/11/22 | 8/10/22 | 11/8/22 | 3/15/23 | 5/12/23 | 8/8/23 | 11/10/23 | 3/15/24 | 5/10/24 | - | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | 6,691 | 6,826 | 13,404 | 13,067 | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.692 x | 3.566 x | - | 13.18 x | - | - | - |
| Free Cash Flow 1 | 296 | 2,170 | -4,194 | -15.3 | - | 1,090 | 2,364 |
| ROE (net income / shareholders' equity) | 14.7% | 7.35% | 0.43% | 4.78% | 7.43% | 10% | 10.8% |
| ROA (Net income/ Total Assets) | 5.1% | 2.34% | 0.11% | 1.16% | 1.89% | 2.71% | 2.91% |
| Assets 1 | 25,344 | 29,061 | 33,224 | 37,064 | 37,645 | 41,587 | 52,010 |
| Book Value Per Share | 30.10 | 30.80 | 28.00 | 31.30 | - | - | - |
| Cash Flow per Share 2 | 3.110 | 9.700 | -11.70 | 1.300 | - | 4.990 | 9.860 |
| Capex 1 | 451 | 771 | 657 | 408 | 650 | 529 | 445 |
| Capex / Sales | 1.78% | 2.72% | 2.13% | 1.21% | 1.71% | 1.31% | 1.04% |
| Announcement Date | 3/19/20 | 3/25/21 | 3/23/22 | 3/15/23 | 3/15/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
86.6
TWD
Average target price
91.5
TWD
Spread / Average Target
+5.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.06% | 815M | |
| +4.27% | 5.09B | |
| +25.41% | 4.87B | |
| +2.03% | 4.06B | |
| +4.46% | 2.75B | |
| +3.20% | 2.02B | |
| +104.07% | 1.29B | |
| +16.27% | 1.06B | |
| -8.40% | 891M | |
| +14.65% | 859M |
- Stock Market
- Equities
- 1736 Stock
- Financials Johnson Health Tech .Co., Ltd.
